Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
Antioxidants · 20.06.2023 · 12 (6) · 1313
DOI: 10.3390/antiox12061313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 20.06.2023. Verfasst von Marie Angèle Cucci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Biological Science, University of Turin, Corso Raffaello 30, 10125 Turin, Italy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Turin, University of Turin, Department of Clinical and Biological Sciences, Department of Sciences and Pharmaceutical Technology.
Abstract (Originalsprache)
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the patients still develop resistance within the first year of therapy. Therefore, understanding the mechanisms of BRAFi/MEKi-acquired resistance has become a priority for researchers. Among others, oxidative stress-related mechanisms have emerged as a major force. The aim of this study was to evaluate the contribution of Nrf2, the master regulator of the cytoprotective and antioxidant response, in the BRAFi/MEKi acquired resistance of melanoma. Moreover, we investigated the mechanisms of its activity regulation and the possible cooperation with the oncogene YAP, which is also involved in chemoresistance. Taking advantage of established in vitro melanoma models resistant to BRAFi, MEKi, or dual resistance to BRAFi/MEKi, we demonstrated that Nrf2 was upregulated in melanoma cells resistant to targeted therapy at the post-translational level and that the deubiquitinase DUB3 participated in the control of the Nrf2 protein stability. Furthermore, we found that Nrf2 controlled the expression of YAP. Importantly, the inhibition of Nrf2, directly or through inhibition of DUB3, reverted the resistance to targeted therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Biological Science, University of Turin, Corso Raffaello 30, 10125 Turin, Italy.
- Department of Scienza e Tecnologia del Farmaco, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.
- Department of Clinical and Biological Sciences-San Luigi Gonzaga Hospital, University of Turin, Regione Gonzole 10, 10043 Orbassano, Turin, Italy.
- Institute of Genetics and Biophysics-IGB-CNR, "A. Buzzati-Traverso", Via Pietro Castellino 111, 80131 Naples, Italy.
ORCID-Profile: Antonella Roetto, Chiara Dianzani, Stefania Pizzimenti
Förderung
- University of Turin
- University of Turin, Department of Clinical and Biological Sciences
- Department of Sciences and Pharmaceutical Technology
Zitieren
APA
Cucci, M. A., Grattarola, M., Monge, C., Roetto, A., Barrera, G., Caputo, E., Dianzani, C., & Pizzimenti, S. (2023). Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma. Antioxidants, 12(6), 1313. https://doi.org/10.3390/antiox12061313
Vancouver
Cucci MA, Grattarola M, Monge C, Roetto A, Barrera G, Caputo E, et al. Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma. Antioxidants. 2023;12(6):1313. doi:10.3390/antiox12061313
BibTeX
@article{Cucci2023,
author = {Cucci, Marie Angèle and Grattarola, Margherita and Monge, Chiara and Roetto, Antonella and Barrera, Giuseppina and Caputo, Emilia and Dianzani, Chiara and Pizzimenti, Stefania},
title = {Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {6},
pages = {1313},
doi = {10.3390/antiox12061313}
}
EUVIMED